发明名称 Antibody variants with enhanced complement activity
摘要 The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
申请公布号 US9475881(B2) 申请公布日期 2016.10.25
申请号 US201313747317 申请日期 2013.01.22
申请人 Xencor, Inc. 发明人 Lazar Gregory A.;Karki Sher Bahadur;Moore Gregory L.
分类号 A61K38/00;C07K1/00;C07K16/00;A61K39/395;A61K39/40;C07K16/28 主分类号 A61K38/00
代理机构 Morgan, Lewis & Bockius, LLP 代理人 Silva Robin M.;MacDougall Christina A.;Morgan, Lewis & Bockius, LLP
主权项 1. A protein comprising a variant Fc region, wherein said variant Fc region comprises the variant 267E/268F/324T/236A/332E as compared to a parent wild-type Fc region and wherein the numbering is according to the EU index.
地址 Monrovia CA US